Mobile

Safety and Efficacy of Two Doses of Anirfrolumab Compared to Placebo in Adult Subjects with Active Proliferative Lupus Nephritis

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-001442-29

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the efficacy of anifrolumab plus standard of care (SOC) compared to placebo plus SOC in subjects with active proliferative lupus nephritis measured by the relative difference in change from baseline to Week 52 in 24-hour urine protein to creatinine ratio (UPCR)

Critère d'inclusion

  • Lupus Nephritis

Liens